Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
Conditions
Interventions
Intervention1: Cancer Margin Detection using multispectral Terahertz and Fluorescence Technology: This study uses multispectral Terahertz and fluorescence technology to differentiate between benign an
Sponsors
Dr Jyotirmayee Dash
Mazumdar Shaw Medical Foundation
Rajiv Gandhi Cancer Institute Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: For Inclusion, an individual must meet all of the following criteria. Inability to meet all inclusion criteria for a cohort will lead to exclusion. 1. Adult males and females, aged 18 years and above 2. Provision of Informed Consent 3. Willing and able to participate in the study and provide tissue samples as per availability and feasibility. 4. No co-morbidities which could impair study participation or sample collection, 5. Female participants: neither pregnant, nor lactating 6. For Study A (Known Cancer Cases) (6a). Diagnosed with any malignancy as per current appropriate Standard of Care approach. (6b). Therapy Naïve as well as received prior anticancer treatments. 7. For Study B (Known Benign Cases) (7a). No prior diagnosis of any cancer. (7b). Confirmed diagnosis of benign (non-cancerous / non-malignant) conditions as per relevant Standard of Care diagnostic work-up.
Exclusion criteria
Exclusion criteria: For Exclusion, an individual may meet any of the following criteria. Meeting even one exclusion criteria will lead to exclusion. 1. Age less than 18 years, 2. Inability to provide Informed Consent, 3. Failure to meet general or study-specific Inclusion Criteria 4. Pregant and lactating female participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cancer margin detection using Terahertz and Fluorescence device with higher sensitivity and specificity. The device can differentiate between benign and malignant tissues.Timepoint: 2 years | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the capability of the Terahertz device as a complementary technique to histopathology.Timepoint: Every 6 months | — |
Countries
India
Contacts
Public ContactDr Jyotirmayee Dash
TeraLumen Solutions Pvt. Ltd.
Outcome results
None listed